joe iniowa

Long time investor, retired from tech space

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics. Recent $8 report.

[Wall St Engine @wallstengine]

Atomera developed a new GaN-on-silicon RF technology aimed at improving performance while lowering substrate costs. $ATOM says testing showed more than 10x lower parasitic interface charge and 1,000x better linearity than reference wafers at 30mW input power.

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics Good interview with CEO Gene Mack. The reversal of Parkinson’s symptoms like return of smell have been maintained through trial.

[Lou Basenese @LouBasenese]

In case you missed The Big Skinny last night...

The SpaceX IPO is a retail trap.

Eli Lilly could double its market cap.

@_JoshSchafer says Micron's got way more room to run, based on 2027 earnings estimate going from $11 to $105 a share.

And Gene Mack, CEO of @GainThera joined to discuss the 150-day Parkinson's data that no one in biotech is talking about yet.

And more! Listen in 👇

All Filling. Zero Fluff.

TIMESTAMPS:
5:13 - Can humans live to 150? The longevity case
10:06 - Why $LLY is a must-own
14:00 - Josh on rising rates and stocks
23:40 - Can $NVDA reach $20 trillion market cap
33:30 - 150-day Parkinson's drug data
51:52 - SpaceX IPO fever and fears
54:18 - Prediction market cheating is here
55:56 - WTF!? ETFs now outnumber stocks
1:01:42 - Zuckerberg's subscription squeeze

$NVDA $SPCX $MU $LLY $GANX $XBI $META

[Avid Trader @RealAvidTrader]

Really Would Like To See $GANX at $100M -$150M Market Cap And Establish a New Floor. Need to Get Out of This Mid-High $1.00 Range

Im Shocked its Still Trading Here, But Thats Just More Opportunities For Retail

The Most Disconnected $1 Stock…
https://t.co/SSUhDx2oLT

[joe iniowa @Microcapreturns]

@RealAvidTrader $GANX Gain Therapeutics another $8 target

[joe iniowa @Microcapreturns]

@Benaart71488 @LouBasenese @benpieter001 $GANX Gain Therapeutics. On today's Lou interview Gene mentioned that the FDA is backed up and latest was they would have their response in 2 weeks.

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics The data is so much better than what they are reporting. People had functions like smell return. Nobody else is doing that.

[Peter @benpieter001]

Screened 250 biotech tickers this month looking for asymmetric setups. One company is outperforming the entire space on clinical data and trading like it's about to delist. Don't miss this 👇

- $GANX (Gain Therapeutics) → $40+ Must buy
I built a full strategic brief on this name: multi-player game theory, CNS comparable-transaction model, Bayesian Phase 2 PoS, and contrarian microstructure analysis. The output is unambiguous.
- Phase 1b Day 150 just delivered −3.0 MDS-UPDRS from baseline in the high-GluSph responder subgroup. Untreated Parkinson's would have worsened these patients +2 in five months. That's a 5-point net swing in the direction no PD drug has ever moved established patients. Every prior disease-modifier (Roche, Biogen, Pfizer, AbbVie) failed at 0 to −1.5 vs. placebo. This one is reversing it.
4.8-point separation between responders (high-GluSph) and non-responders (low-GluSph) is the cleanest biomarker stratification signal in PD trial history — it tells you exactly which patients the drug works on. FDA-grade enrichment data on a $76M market cap.
I ran a game theory scenario with $400B pharma patent cliff 2026-2030 looming over Big Pharma forcing them into M&A (from late stage to early - pre-clinical in that order). Lilly has a reflexive defense problem (owns Prevail/PR001). Tier-2 buyers (Sanofi, AbbVie, Novartis) carry implicit $600-800M bid floor. GANX is signaling availability... zero Phase-2 hires posted.
Strategic value: $1.5–5B. P(≥$2B takeover in 18 months): ~25%. Stock at $1.80 --> should be at $20 with a upside premium (CVR or straight buy-out)

I never get asked why I don't turn this into paid content, but for me, sharing stock information is not just a hobby, I do this for fun, because I can't help my self to go deep on contect.. I share it for free because I believe the world is missing out on this gem.

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics able to return functions with Parkinson's drug GT-02287

Most common benefits reported by study participants include meaningful improvements in specific functional areas such as smell and taste, sleep, and balance or gait

https://t.co/HrMBfI4hYJ

[joe iniowa @Microcapreturns]

$GANX New NPR interview out in front of this week's GBA1 data presentation.

BioTech Nation ... with Dr. Moira Gunn | A Different Way to Treat Parkinson's...Dr. Jonas Hannestad & Dr. Joanne Taylor, Gain Therapeutics

https://t.co/sOtj19Yhrv

[Pennybois Trade Alerts @PennyboisTrades]

🚨 $GANX - GT-02287 update: Lead drug is a first-in-class GCase modulator for Parkinson’s disease.

Current data shows 16 patients in the extension, with 14 past the 150-day mark holding stable UPDRS scores. Biomarkers show an 81% reduction in CSF GluSph.

Phase 2 launch set for Q3 2026. $16.5M cash on hand; 4 Strong Buys.

Communicated Disclaimer - https://t.co/8HknYytYds

[joe iniowa @Microcapreturns]

$GANX New NPR interview out.

BioTech Nation ... with Dr. Moira Gunn | A Different Way to Treat Parkinson's...Dr. Jonas Hannestad & Dr. Joanne Taylor, Gain Therapeutics

https://t.co/sOtj19Yhrv

[Boudin @boudin420]

$GANX 👇

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics on NPR this week and presenting Phase 1b Parkinsons data at GBA1 Conference on Friday.

BioTech Nation ... with Dr. Moira Gunn | A Different Way to Treat Parkinson's...Dr. Jonas Hannestad & Dr. Joanne Taylor, Gain Therapeutics

https://t.co/sOtj19Yhrv

[Avid Trader @RealAvidTrader]

The Most Disconnected $1
Stock I’ve Ever Seen (Massive)

👉(https://t.co/SSUhDx2oLT)👈

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics will present at GBA1 conference extended data of current Phase 1b Parkinsons trial where they have reversed Parkinson's in 80% of patients at 150 days. Next up 180+ day data.

[Avid Trader @RealAvidTrader]

$GANX Great Video, This Company Has Incredible Potential, Im Looking Forward To The Last Week in May (22nd) For The Company Presentation

“An Update on The Development of The Modulator GT-02287 For Parkinson’s Disease”

$80M Market Cap Currently

I See Billion Dollar Potential

[Lou Basenese @LouBasenese]

What if Parkinson’s didn’t have to get worse?

$GANX reported updated data showing no decline in motor scores – something rarely seen in this disease.

I sat down with CEO Gene Mack again to break it all down 👇

https://t.co/HSIvSrjDRg

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics. Recent scientific article validates Gain's approach that increasing GCase can slow, stop and maybe reverse trajectory of Parkinson’s.

https://t.co/skvEDXOq7w

[Avid Trader @RealAvidTrader]

$COYA $GANX

Thats All I Will Say Folks

Some Get it, Others Don’t

Fundamentals > Stock Price

[BoldStocksBabe @Boldstocksbabe]

🚨 Saturday Sassy Small Cap Freedom Fuel:
Gain Therapeutics $GANX
is turning heads with key conference presentations on next-gen therapies — right as macro tailwinds hit pharma hard!
This week’s updates drove solid momentum and attention.
@GainThera is building the future of precision medicine the pro-America way!
Full Details: https://t.co/g2ySVxvoFr

#Biotech #Pharma #SmallCap #MAGA #BoldStocks #StockQueen

[joe iniowa @Microcapreturns]

@Rick_in_Miami My thoughts if they have improved 6 points after about a year of Parkinson’s time which would normally be a plus 4 that's almost a 3 year improvement. Plus getting smell back is reversing.

[joe iniowa @Microcapreturns]

$GANX Gain Therapeutics Parkinsons showing that it continues to reverse Parkinsons after 150 days. Amazing.

[Crwe World @CrweWorld]

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 $GANX https://t.co/GgzkHK8ouo

[Voltaire @PhilipEtienne]

Thank you to loose hands in $GANX for the early birthday present-buying this dip ahead of next weeks conf is more than prudent-nice to be long with an almost legendary group of investors and experts-truly the first disease modifying drug for any central nervous system disease 🥷